INDIANAPOLIS (March 21, 2023) — BioCrossroads announced today that Jane Dunigan-Smith and Mike Bolinder have joined the organization’s leadership team.
Dunigan-Smith, senior vice president, chief strategy officer and managing director of Seed Funds, comes to BioCrossroads after 19 years with Eli Lilly and Company where she spent a significant portion of her career in commercialization, corporate strategy and operations. She also has a strong background in accounting and finance, having spent the early part of her career as a Certified Public Accountant, and serves on the boards of Diagnotes, Inc. and Allinaire Therapeutics.
“Jane’s multi-faceted experience positions her to manage the Seed Funds and lead our strategy at a time when Indiana’s life sciences sector is expanding and innovating in multiple areas,” said Patty Martin, president and CEO, BioCrossroads. “One example is our work to establish Indiana as a global player in the field of radiopharmaceuticals. Her experience in pharmaceutical commercialization will be key as we develop strategic plans to support other promising sub-sectors while continuing to support our already established strengths in pharmaceuticals and biologics, medical devices and equipment, medical, research and testing laboratories and contract manufacturing organizations.”
Bolinder, senior vice president, external engagement, and chief innovation officer, has served in the life sciences sector for 20 years, most recently as CEO and executive director of Acacia Pharma Group plc, a publicly listed group of companies with headquarters in both Indianapolis, Ind., and Cambridge, UK. Prior to Acacia, he served as head of marketing and commercial strategy for the hospital division of Mallinckrodt Pharmaceuticals, following their acquisition of Cadence Pharmaceuticals. Previously, he worked at Eli Lilly and Company in various commercial roles of increasing responsibility.
“Mike has an ideal combination of experience working with large corporate and start-up entities to make an immediate impact through BioCrossroads,” said Martin. “There are so many opportunities ahead to continue to grow this sector, and he will be able to utilize his knowledge and experience to make some great things happen.”
BioCrossroads is Indiana’s initiative to grow, advance and invest in the life sciences, a public-private collaboration that supports the region’s existing research and corporate strengths while encouraging new business development. BioCrossroads invests capital and provides support to life sciences businesses, launches new life sciences enterprises (Indiana Biosciences Research Institute, 16 Tech, Indiana Health Information Exchange, and OrthoWorx ), expands collaboration and partnerships among Indiana’s life science institutions, promotes science education and markets Indiana’s life sciences industry.